Eli Lilly and Partners

Since 2003, Lilly has worked hand in hand with its partners to prevent multidrug-resistant tuberculosis (MDR-TB) from gaining ground and taking more lives. Now funded by the Eli Lilly and Company Foundation, the Lilly MDR-TB Partnership brings together government leaders, global health organizations, country-level healthcare providers, community and advocacy organizations and other stakeholders to increase the availability of quality-assured medicine used to treat MDR-TB, enhance education for healthcare professionals where the need is greatest, and raise awareness of the disease amongst communities most at risk.


Lilly collaborates with its partner organizations working to improve outcomes for people who have multidrug-resistant tuberculosis (MDR-TB). Formed in 2003, the Lilly MDR-TB Partnership seeks to increase the access and availability of MDR-TB treatments, while also improving education for healthcare professionals and raising awareness amongst communities most at risk.